Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 1,975 | 312 | 1,630 |
| Samples | 1,487 | 239 | 1,219 |
| Peptides | 1,138 | 168 | 1,002 |
Function
NALCN · Sodium leak channel, non-selective
This gene encodes a voltage-independent, nonselective cation channel which belongs to a family of voltage-gated sodium and calcium channels that regulates the resting membrane potential and excitability of neurons. This family is expressed throughout the nervous system and conducts a persistent sodium leak current that contributes to tonic neuronal excitability. The encoded protein forms a channelosome complex that includes G-protein-coupled receptors, UNC-79, UNC-80, NCA localization factor-1, and src family tyrosine kinases. Naturally occurring mutations in this gene are associated with infantile neuroaxonal dystrophy, infantile hypotonia with psychomotor retardation and characteristic facies (IHPRF) syndrome, and congenital contractures of the limbs and face with hypotonia and developmental delay (CLIFAHDD) syndrome. A knockout of the orthologous gene in mice results in paralysis with a severely disrupted respiratory rhythm, and lethality within 24 hours after birth. [provided by RefSeq, Apr 2017].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 1128 amino-acid changes on canonical ENST00000251127 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in NALCN · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in NALCN – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Non-Small Cell Lung Carcinoma | 51/304 17% | 119/1390 9% |
| Endometrial Carcinoma | 10/42 24% | 53/612 9% |
| Chronic Myelogenous Leukemia | 2/25 8% | 0/0 0% |
| Acute Myeloid Leukemia | 7/90 8% | 0/0 0% |
| T-Cell Non-Hodgkins Lymphoma | 2/26 8% | 0/0 0% |
| T-Lymphoblastic Leukemia | 3/40 8% | 0/0 0% |
| Melanoma | 14/210 7% | 133/1899 7% |
| Colorectal Carcinoma | 29/143 20% | 206/3239 6% |
| Gastric Carcinoma | 11/74 15% | 118/1809 7% |
| Squamous Cell Lung Carcinoma | 8/57 14% | 48/810 6% |
| Other Solid Cancers | 5/94 5% | 91/1515 6% |
| Glioblastoma | 4/98 4% | 0/0 0% |
| Oral Cavity Carcinoma | 2/54 4% | 0/0 0% |
| Neuroendocrine Tumour | 14/154 9% | 11/577 2% |
| Esophageal Carcinoma | 1/23 4% | 26/769 3% |
| Bladder Carcinoma | 4/58 7% | 27/956 3% |
| Small Cell Lung Carcinoma | 0/9 0% | 23/752 3% |
| Head and Neck Carcinoma | 3/85 4% | 38/1574 2% |
| Cervical Carcinoma | 2/35 6% | 8/422 2% |
| Hepatocellular Carcinoma | 4/46 9% | 43/2210 2% |
| Non-Cancerous | 0/104 0% | 17/830 2% |
| Esophageal Squamous Cell Carcinoma | 6/51 12% | 41/2550 2% |
| Adrenocortical Carcinoma | 0/3 0% | 2/112 2% |
| Ovarian Carcinoma | 3/109 3% | 16/998 2% |
| Pancreatic Carcinoma | 3/89 3% | 26/1611 2% |
| Other Sarcomas | 2/69 3% | 11/699 2% |
| Germ Cell Tumour | 1/25 4% | 2/169 1% |
| Breast Carcinoma | 8/144 6% | 44/3264 1% |
| Biliary Tract Carcinoma | 4/54 7% | 11/950 1% |
| Hodgkins Lymphoma | 0/16 0% | 2/122 2% |
Mutation Distribution
Where NALCN is mutated · all tissues, split by cell line vs tissue
How many mutations in NALCN were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 1,975 mutations in NALCN
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|